159 related articles for article (PubMed ID: 29203403)
1. Carcinogenicity assessment of baricitinib in Tg.rasH2 mice and Sprague-Dawley (Crl:CD) rats.
Carfagna M; Cannady E; Ryan T; Herman J; Truex L; Narwani K; Sullivan J
Regul Toxicol Pharmacol; 2018 Feb; 92():458-471. PubMed ID: 29203403
[TBL] [Abstract][Full Text] [Related]
2. Results from oral gavage carcinogenicity studies of ruxolitinib in Tg.rasH2 mice and Sprague-Dawley (Crl:CD) rats.
Shuey DL; Oliver J; Zhou G; Roberts A
Regul Toxicol Pharmacol; 2016 Nov; 81():305-315. PubMed ID: 27647628
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.
Papp KA; Menter MA; Raman M; Disch D; Schlichting DE; Gaich C; Macias W; Zhang X; Janes JM
Br J Dermatol; 2016 Jun; 174(6):1266-76. PubMed ID: 26800231
[TBL] [Abstract][Full Text] [Related]
4. Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials.
Harigai M; Takeuchi T; Smolen JS; Winthrop KL; Nishikawa A; Rooney TP; Saifan CG; Issa M; Isaka Y; Akashi N; Ishii T; Tanaka Y
Mod Rheumatol; 2020 Jan; 30(1):36-43. PubMed ID: 30784354
[No Abstract] [Full Text] [Related]
5. Toxicology and carcinogenesis studies of androstenedione (CAS No. 63-05-8) in F344/N rats and B6C3F1 mice (gavage studies).
Natl Toxicol Program Tech Rep Ser; 2010 Sep; (560):1, 7-31,33-171 passim. PubMed ID: 21037592
[TBL] [Abstract][Full Text] [Related]
6. Twenty-six-Week carcinogenicity study of chloroform in CB6F1 rasH2-transgenic mice.
Sehata S; Maejima T; Watanabe M; Ogata S; Makino T; Tanaka K; Manabe S; Takaoka M
Toxicol Pathol; 2002; 30(3):328-38. PubMed ID: 12051550
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Carcinogenic Potential of Enarodustat (JTZ-951), a Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor, in 26-Week Tg.rasH2 Mouse Study and 2-Year Sprague-Dawley Rat Study.
Kemmochi Y; Toyoda K; Ishida T; Yasui Y; Shoda T
Int J Toxicol; 2023 Dec; 42(6):489-503. PubMed ID: 37480334
[TBL] [Abstract][Full Text] [Related]
8. Twenty-six-week oral carcinogenicity study of 3-monochloropropane-1,2-diol in CB6F1-rasH2 transgenic mice.
Lee BS; Park SJ; Kim YB; Han JS; Jeong EJ; Son HY; Moon KS
Arch Toxicol; 2017 Jan; 91(1):453-464. PubMed ID: 27017489
[TBL] [Abstract][Full Text] [Related]
9. Toxicology and carcinogenesis studies of 3,3',4,4'-tetrachloroazobenzene (TCAB) (CAS No. 14047-09-7) in Harlan Sprague-Dawley rats and B6C3F1 mice (gavage studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2010 Nov; (558):1-206. PubMed ID: 21383777
[TBL] [Abstract][Full Text] [Related]
10. NTP technical report on the toxicology and carcinogenesis studies of Elmiron (Cas No. 37319-17-8) in F344/N rats and B6C3F1 mice (Gavage Studies).
National Toxicology Program, Public Health Services, National Institutes of Health, US Department of Health and Human Services,
Natl Toxicol Program Tech Rep Ser; 2004 May; (512):7-289. PubMed ID: 15213766
[TBL] [Abstract][Full Text] [Related]
11. Toxicology and carcinogenesis studies of o-nitrotoluene sulfone (CAS no. 88-72-2) in F344/N rats and B6C3F(1) mice (feed studies).
National Toxicology Program, Public Health Service, National Institutes of Health, US Department of Health and Human Services
Natl Toxicol Program Tech Rep Ser; 2002 May; (504):1-357. PubMed ID: 12087420
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study.
Tanaka Y; Emoto K; Cai Z; Aoki T; Schlichting D; Rooney T; Macias W
J Rheumatol; 2016 Mar; 43(3):504-11. PubMed ID: 26834213
[TBL] [Abstract][Full Text] [Related]
13. The Tg rasH2 mouse in cancer hazard identification.
Morton D; Alden CL; Roth AJ; Usui T
Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
[TBL] [Abstract][Full Text] [Related]
14. Toxicology and carcinogenesis studies of riddelliine (CAS No. 23246-96-0) in F344/N rats and B6C3F1 mice (gavage studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2003 May; (508):1-280. PubMed ID: 12844193
[TBL] [Abstract][Full Text] [Related]
15. NTP Toxicology and Carcinogenesis Studies of Salicylazosulfapyridine (CAS No. 599-79-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1997 May; 457():1-327. PubMed ID: 12587019
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
Keystone EC; Taylor PC; Drescher E; Schlichting DE; Beattie SD; Berclaz PY; Lee CH; Fidelus-Gort RK; Luchi ME; Rooney TP; Macias WL; Genovese MC
Ann Rheum Dis; 2015 Feb; 74(2):333-40. PubMed ID: 25431052
[TBL] [Abstract][Full Text] [Related]
17. NTP technical report on the toxicology and carcinogenesis studies of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (CAS No. 1746-01-6) in female Harlan Sprague-Dawley rats (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2006 Apr; (521):4-232. PubMed ID: 16835633
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers.
Shi JG; Chen X; Lee F; Emm T; Scherle PA; Lo Y; Punwani N; Williams WV; Yeleswaram S
J Clin Pharmacol; 2014 Dec; 54(12):1354-61. PubMed ID: 24965573
[TBL] [Abstract][Full Text] [Related]
19. The 26-week Tg.rasH2 mice carcinogenicity studies: microscopic examination of only select tissues in low- and mid-dose groups.
Paranjpe MG; Denton MD; Elbekai RH
Toxicol Pathol; 2014 Oct; 42(7):1153-7. PubMed ID: 23960167
[TBL] [Abstract][Full Text] [Related]
20. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
